Quyen T. Nguyen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Quyen T. Nguyen has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
Roger Y. Tsien
Department of Pharmacology, University of California, San Diego, California, USA Howard Hughes Medical Institute, San Diego, California, USA
4 shared publicationsBeth Friedman
Department of Pharmacology, University of California at San Diego, La Jolla, CA 92093-0647, USA
3 shared publicationsPaul Steinbach
Authors' Affiliations: 1Department of Pharmacology, 2Division of Head and Neck Surgery, 3Department of Pathology, and 4Howard Hughes Medical Institute, University of California at San Diego, La Jolla, California
3 shared publicationsTao Jiang
Authors' Affiliations: 1Department of Pharmacology, 2Division of Head and Neck Surgery, 3Department of Pathology, and 4Howard Hughes Medical Institute, University of California at San Diego, La Jolla, California
3 shared publicationsAmy P. Wu
Division of Otolaryngology/Head and Neck Surgery; †Departments of Neurosurgery, and ‡Head and Neck Surgery, Kaiser Permanente, San Diego, California, U.S.A.
2 shared publicationsJessica L. Crisp
Department of Chemistry and Biochemistry, University of California at San Diego, La Jolla, CA 92093-0647, USA
2 shared publications
Latest Publications
- 4 August 2014
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 151 (4) , 612-618
Matrix‐Metalloproteinases in Head and Neck Carcinoma–Cancer Genome Atlas Analysis and Fluorescence Imaging in Mice
(1) Obtain matrix-metalloproteinase (MMP) expression profiles for head and neck squamous cell carcinoma (HNSCC) specimens from the Cancer Genomic Atlas (TCGA). (2) Demonstrate HNSCC imaging using MMP-cleavable, fluorescently labeled ratiometric activatable cell-penetrating peptide (RACPP). Retrospective human cohort study; prospective animal study. Translational research laboratory. Patient clinical data and mRNA expression levels of MMP genes were downloaded from TCGA data portal. RACPP provides complementary ratiometric fluorescent contrast (increased Cy5 and decreased Cy7 intensities) when cleaved by MMP2/9. HNSCC–tumor bearing mice were imaged in vivo after RACPP injection. Histology was evaluated by a pathologist blinded to experimental conditions. Zymography confirmed MMP-2/9 activity in xenografts. RACPP was applied to homogenized human HNSCC specimens, and ratiometric fluorescent signal was measured on a microplate reader for ex vivo analysis. Expression of multiple MMPs including MMP2/9 is greater in patient HNSCC tumors than matched control tissue. In patients with human papilloma virus positive (HPV+) tumors, higher MMP2 and MMP14 expression correlates with worse 5-year survival. Orthotopic tongue HNSCC xenografts showed excellent ratiometric fluorescent labeling with MMP2/9-cleavable RACPP (sensitivity = 95.4%, specificity = 95.0%). Fluorescence ratios were greater in areas of higher tumor burden (P < .03), which is useful for intraoperative margin assessment. Ex vivo, human HNSCC specimens showed greater cleavage of RACPP when compared to control tissue (P = .009). Human HNSCC tumors show increased mRNA expression of multiple MMPs including MMP2/9. We used RACPP, a ratiometric fluorescence assay of MMP2/9 activity, to show improved occult tumor identification and margin clearance. Ex vivo assays using RACPP in biopsy specimens may identify patients who will benefit from intraoperative RACPP use.
- 4 August 2014
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 151 (4) , 612-618
Matrix‐Metalloproteinases in Head and Neck Carcinoma–Cancer Genome Atlas Analysis and Fluorescence Imaging in Mice
(1) Obtain matrix-metalloproteinase (MMP) expression profiles for head and neck squamous cell carcinoma (HNSCC) specimens from the Cancer Genomic Atlas (TCGA). (2) Demonstrate HNSCC imaging using MMP-cleavable, fluorescently labeled ratiometric activatable cell-penetrating peptide (RACPP). Retrospective human cohort study; prospective animal study. Translational research laboratory. Patient clinical data and mRNA expression levels of MMP genes were downloaded from TCGA data portal. RACPP provides complementary ratiometric fluorescent contrast (increased Cy5 and decreased Cy7 intensities) when cleaved by MMP2/9. HNSCC–tumor bearing mice were imaged in vivo after RACPP injection. Histology was evaluated by a pathologist blinded to experimental conditions. Zymography confirmed MMP-2/9 activity in xenografts. RACPP was applied to homogenized human HNSCC specimens, and ratiometric fluorescent signal was measured on a microplate reader for ex vivo analysis. Expression of multiple MMPs including MMP2/9 is greater in patient HNSCC tumors than matched control tissue. In patients with human papilloma virus positive (HPV+) tumors, higher MMP2 and MMP14 expression correlates with worse 5-year survival. Orthotopic tongue HNSCC xenografts showed excellent ratiometric fluorescent labeling with MMP2/9-cleavable RACPP (sensitivity = 95.4%, specificity = 95.0%). Fluorescence ratios were greater in areas of higher tumor burden (P < .03), which is useful for intraoperative margin assessment. Ex vivo, human HNSCC specimens showed greater cleavage of RACPP when compared to control tissue (P = .009). Human HNSCC tumors show increased mRNA expression of multiple MMPs including MMP2/9. We used RACPP, a ratiometric fluorescence assay of MMP2/9 activity, to show improved occult tumor identification and margin clearance. Ex vivo assays using RACPP in biopsy specimens may identify patients who will benefit from intraoperative RACPP use.
- 15 January 2013
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 73 (2) , 855-864
Real-time In Vivo Molecular Detection of Primary Tumors and Metastases with Ratiometric Activatable Cell-Penetrating Peptides
Management of metastatic disease is integral to cancer treatment. Evaluation of metastases often requires surgical removal of all anatomically susceptible lymph nodes for ex vivo pathologic examination. We report a family of novel ratiometric activatable cell-penetrating peptides, which contain Cy5 as far red fluorescent donor and Cy7 as near-infrared fluorescent acceptor. Cy5 is quenched in favor of Cy7 re-emission until the intervening linker is cut by tumor-associated matrix metalloproteinases-2 and 9 (MMP2,9) or elastases. Such cleavage increases the Cy5:Cy7 emission ratio 40-fold and triggers tissue retention of the Cy5-containing fragment. This ratiometric increase provides an accelerated and quantifiable metric to identify primary tumors and metastases to liver and lymph nodes with increased sensitivity and specificity. This technique represents a significant advance over existing nonratiometric protease sensors and sentinel lymph node detection methods, which give no information about cancer invasion. Cancer Res; 73(2); 855–64. ©2012 AACR.
- 15 January 2013
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 73 (2) , 855-864
Real-time In Vivo Molecular Detection of Primary Tumors and Metastases with Ratiometric Activatable Cell-Penetrating Peptides
Management of metastatic disease is integral to cancer treatment. Evaluation of metastases often requires surgical removal of all anatomically susceptible lymph nodes for ex vivo pathologic examination. We report a family of novel ratiometric activatable cell-penetrating peptides, which contain Cy5 as far red fluorescent donor and Cy7 as near-infrared fluorescent acceptor. Cy5 is quenched in favor of Cy7 re-emission until the intervening linker is cut by tumor-associated matrix metalloproteinases-2 and 9 (MMP2,9) or elastases. Such cleavage increases the Cy5:Cy7 emission ratio 40-fold and triggers tissue retention of the Cy5-containing fragment. This ratiometric increase provides an accelerated and quantifiable metric to identify primary tumors and metastases to liver and lymph nodes with increased sensitivity and specificity. This technique represents a significant advance over existing nonratiometric protease sensors and sentinel lymph node detection methods, which give no information about cancer invasion. Cancer Res; 73(2); 855–64. ©2012 AACR.
- 26 April 2012
- Published by Oxford University Press (OUP) in Integrative Biology
- Vol. 4 (6) , 595-605
In vivofluorescence imaging of atherosclerotic plaques with activatable cell-penetrating peptides targeting thrombin activity
Development of a novel injectable probe for in vivo thrombin detection in advanced atherosclerotic plaques with high spatial resolution. Probe may be further de
- 26 April 2012
- Published by Oxford University Press (OUP) in Integrative Biology
- Vol. 4 (6) , 595-605
In vivofluorescence imaging of atherosclerotic plaques with activatable cell-penetrating peptides targeting thrombin activity
Development of a novel injectable probe for in vivo thrombin detection in advanced atherosclerotic plaques with high spatial resolution. Probe may be further de
- 1 April 2012
- Published by Wolters Kluwer Health in Otology & Neurotology
- Vol. 33 (3) , 455-458
Impact of Fundal Extension on Hearing After Surgery for Vestibular Schwannomas
Objective To compare hearing preservation after surgery for intracanalicular vestibular schwannomas with or without fundal extension. Study Design Retrospective chart review. Patients Patients with intracanalicular tumors (≤10-m maximal dimension) undergoing retrosigmoid craniotomy between 2001 and 2010. Intervention Preoperative and postoperative audiograms, preoperative magnetic resonance imaging, and operative reports were reviewed. Main Outcome Measures Preoperative and postoperative hearing (American Academy of Otolaryngology–Head and Neck Surgery classification). Results Complete data for 53 patients (27 female and 24 male subjects, sex was not recorded for 2 patients) meeting selection criteria was available. Fundal involvement was identified in 39 (73.6%) of the 53 patients. The remaining 14 patients did not have tumor with fundal extension (26.4%). Average tumor size for patients with fundal extension (+FE) was 6.9 ± 2.2 mm and without fundal extension (–FE) was 8.2 ± 1.9 mm (p = 0.05, Student’s t test). Average preoperative speech discrimination score for the entire study was 90.5 ± 11.8 (n = 53). After retrosigmoid approach for tumor resection, 79% of patients (42/53) had preserved hearing defined as American Academy of Otolaryngology–Head and Neck Surgery class A, B, or C. Average postoperative speech discrimination score for these patients was 89.3 ± 12.1, and average postoperative pure-tone average was 35.9 ± 9.1%. Eighty-five percent (33/39) of +FE patients had preserved hearing (class A, B, or C). In contrast, 64% (9/14) of –FE patients had hearing preserved (class A, B, or C; Fisher’s exact test, p = 0.034). Conclusion Hearing preservation rate after retrosigmoid craniotomy for intracanalicular vestibular schwannomas may be superior for tumors with fundal extension compared with tumors that do not extend to the fundus.
- 1 April 2012
- Published by Wolters Kluwer Health in Otology & Neurotology
- Vol. 33 (3) , 455-458
Impact of Fundal Extension on Hearing After Surgery for Vestibular Schwannomas
Objective To compare hearing preservation after surgery for intracanalicular vestibular schwannomas with or without fundal extension. Study Design Retrospective chart review. Patients Patients with intracanalicular tumors (≤10-m maximal dimension) undergoing retrosigmoid craniotomy between 2001 and 2010. Intervention Preoperative and postoperative audiograms, preoperative magnetic resonance imaging, and operative reports were reviewed. Main Outcome Measures Preoperative and postoperative hearing (American Academy of Otolaryngology–Head and Neck Surgery classification). Results Complete data for 53 patients (27 female and 24 male subjects, sex was not recorded for 2 patients) meeting selection criteria was available. Fundal involvement was identified in 39 (73.6%) of the 53 patients. The remaining 14 patients did not have tumor with fundal extension (26.4%). Average tumor size for patients with fundal extension (+FE) was 6.9 ± 2.2 mm and without fundal extension (–FE) was 8.2 ± 1.9 mm (p = 0.05, Student’s t test). Average preoperative speech discrimination score for the entire study was 90.5 ± 11.8 (n = 53). After retrosigmoid approach for tumor resection, 79% of patients (42/53) had preserved hearing defined as American Academy of Otolaryngology–Head and Neck Surgery class A, B, or C. Average postoperative speech discrimination score for these patients was 89.3 ± 12.1, and average postoperative pure-tone average was 35.9 ± 9.1%. Eighty-five percent (33/39) of +FE patients had preserved hearing (class A, B, or C). In contrast, 64% (9/14) of –FE patients had hearing preserved (class A, B, or C; Fisher’s exact test, p = 0.034). Conclusion Hearing preservation rate after retrosigmoid craniotomy for intracanalicular vestibular schwannomas may be superior for tumors with fundal extension compared with tumors that do not extend to the fundus.
- 15 August 2011
- Published by Wiley in The Laryngoscope
- Vol. 121 (S5) , S293
Visualizing transgenic murine papillary thyroid cancer with novel nerve peptide and protease-dependent tumor-targeting peptides
- 15 August 2011
- Published by Wiley in The Laryngoscope
- Vol. 121 (S5) , S293
Visualizing transgenic murine papillary thyroid cancer with novel nerve peptide and protease-dependent tumor-targeting peptides
- Open Access
- 16 February 2011
- Published by Wiley in The Laryngoscope
- Vol. 121 (4) , 805-810
Improved facial nerve identification with novel fluorescently labeled probe
Objectives/Hypothesis: By phage display, we have developed a novel peptide (NP41) that binds selectively to nerves following systemic administration. We evaluated the pattern of facial nerve labeling with fluorescently‐labeled NP41 (F‐NP41). We also tested whether F‐NP41 highlights facial nerves well enough to identify nerve stumps accurately several weeks after nerve transection.Study Design: Forty‐seven wild‐type mice were studied prospectively. One surgeon performed the nerve transection, reanastomoses, and monitoring of functional recovery.Methods: Fluorescent labeling: F‐NP41 was administered intravenously (20 mice). Nerve labeling was studied with fluorescence microscopy. Transection and reanastomosis: the right facial nerve was transected (25 mice). Three weeks after transection, F‐NP41 was administered intravenously and fluorescence microscopy was used to identify the nerve stumps and reanastomosis in one group. Nerve identification and renastomosis was performed with white light in another group without F‐NP41. The control group underwent sham surgery. Time to nerve identification was recorded. Functional recovery was monitored for at least 8 weeks.Results: We found excellent labeling of intact and transected facial nerves following F‐NP41 administration. Several weeks following nerve transection, F‐NP41 provided accurate identification of the proximal and distal nerve stumps. Following reanastomosis, time to recovery and level of functional recovery was similar in the absence and presence of F‐NP41.Conclusions: We show improved visualization of facial nerves with a novel systemically applied fluorescently labeled probe. Use of F‐NP41 resulted in accurate identification of facial nerve stumps several weeks following transection. Functional recovery was similar with and without the use of F‐NP41. Laryngoscope, 2011
- 16 February 2011
- Published by Wiley in The Laryngoscope
- Vol. 121 (4) , 805-810
Open AccessImproved facial nerve identification with novel fluorescently labeled probe
Objectives/Hypothesis: By phage display, we have developed a novel peptide (NP41) that binds selectively to nerves following systemic administration. We evaluated the pattern of facial nerve labeling with fluorescently‐labeled NP41 (F‐NP41). We also tested whether F‐NP41 highlights facial nerves well enough to identify nerve stumps accurately several weeks after nerve transection.Study Design: Forty‐seven wild‐type mice were studied prospectively. One surgeon performed the nerve transection, reanastomoses, and monitoring of functional recovery.Methods: Fluorescent labeling: F‐NP41 was administered intravenously (20 mice). Nerve labeling was studied with fluorescence microscopy. Transection and reanastomosis: the right facial nerve was transected (25 mice). Three weeks after transection, F‐NP41 was administered intravenously and fluorescence microscopy was used to identify the nerve stumps and reanastomosis in one group. Nerve identification and renastomosis was performed with white light in another group without F‐NP41. The control group underwent sham surgery. Time to nerve identification was recorded. Functional recovery was monitored for at least 8 weeks.Results: We found excellent labeling of intact and transected facial nerves following F‐NP41 administration. Several weeks following nerve transection, F‐NP41 provided accurate identification of the proximal and distal nerve stumps. Following reanastomosis, time to recovery and level of functional recovery was similar in the absence and presence of F‐NP41.Conclusions: We show improved visualization of facial nerves with a novel systemically applied fluorescently labeled probe. Use of F‐NP41 resulted in accurate identification of facial nerve stumps several weeks following transection. Functional recovery was similar with and without the use of F‐NP41. Laryngoscope, 2011
- 6 February 2011
- Published by Springer Nature in Nature Biotechnology
- Vol. 29 (4) , 352-356
Fluorescent peptides highlight peripheral nerves during surgery in mice
The inadvertent cutting of nerves is a common adverse event during surgery. To ease visual identification of nerve fibers, Whitney et al. use phage display to develop a peptide that specifically stains peripheral nerves in living mice and in human tissue samples. Nerve preservation is an important goal during surgery because accidental transection or injury leads to significant morbidity, including numbness, pain, weakness or paralysis. Nerves are usually identified by their appearance and relationship to nearby structures or detected by local electrical stimulation (electromyography), but thin or buried nerves are sometimes overlooked. Here, we use phage display to select a peptide that binds preferentially to nerves. After systemic injection of a fluorescently labeled version of the peptide in mice, all peripheral nerves are clearly delineated within 2 h. Contrast between nerve and adjacent tissue is up to tenfold, and useful contrast lasts up to 8 h. No changes in behavior or activity are observed after treatment, indicating a lack of obvious toxicity. The fluorescent probe also labels nerves in human tissue samples. Fluorescence highlighting is independent of axonal integrity, suggesting that the probe could facilitate surgical repair of injured nerves and help prevent accidental transection.
- 6 February 2011
- Published by Springer Nature in Nature Biotechnology
- Vol. 29 (4) , 352-356
Fluorescent peptides highlight peripheral nerves during surgery in mice
The inadvertent cutting of nerves is a common adverse event during surgery. To ease visual identification of nerve fibers, Whitney et al. use phage display to develop a peptide that specifically stains peripheral nerves in living mice and in human tissue samples. Nerve preservation is an important goal during surgery because accidental transection or injury leads to significant morbidity, including numbness, pain, weakness or paralysis. Nerves are usually identified by their appearance and relationship to nearby structures or detected by local electrical stimulation (electromyography), but thin or buried nerves are sometimes overlooked. Here, we use phage display to select a peptide that binds preferentially to nerves. After systemic injection of a fluorescently labeled version of the peptide in mice, all peripheral nerves are clearly delineated within 2 h. Contrast between nerve and adjacent tissue is up to tenfold, and useful contrast lasts up to 8 h. No changes in behavior or activity are observed after treatment, indicating a lack of obvious toxicity. The fluorescent probe also labels nerves in human tissue samples. Fluorescence highlighting is independent of axonal integrity, suggesting that the probe could facilitate surgical repair of injured nerves and help prevent accidental transection.
- 1 December 2010
- Vol. 31 (9) , 1409-11
Erosive external otitis: a novel distinct clinical entity of the external auditory canal in nonimmunosuppressed individuals.
We introduce erosive external otitis (EEO) as a novel erosive process of the external auditory canal in the absence of diabetes or immune suppression. Case series and literature review. Tertiary referral center. Primary eligibility criteria included patients who had an erosive process of their external auditory canal in the absence of diabetes or immune suppression. Surgical debridement and split-thickness skin grafting. Uneventful wound healing and disease-free long-term follow-up after surgical debridement and skin grafting. Three cases of EEO in the absence of immune suppression or diabetes were diagnosed and treated. All patients required surgical debridement and skin grafting as part of their management. All recovered uneventfully from surgery and had no evidence of recurrence on long-term follow-up. We propose that EEO, which occurs in the absence of immune suppression or diabetes, is a clinical entity that is distinct from the more commonly diagnosed malignant external otitis and that the management of EEO is primarily surgical debridement with skin grafting.
- 1 December 2010
- Vol. 31 (9) , 1409-11
Erosive external otitis: a novel distinct clinical entity of the external auditory canal in nonimmunosuppressed individuals.
We introduce erosive external otitis (EEO) as a novel erosive process of the external auditory canal in the absence of diabetes or immune suppression. Case series and literature review. Tertiary referral center. Primary eligibility criteria included patients who had an erosive process of their external auditory canal in the absence of diabetes or immune suppression. Surgical debridement and split-thickness skin grafting. Uneventful wound healing and disease-free long-term follow-up after surgical debridement and skin grafting. Three cases of EEO in the absence of immune suppression or diabetes were diagnosed and treated. All patients required surgical debridement and skin grafting as part of their management. All recovered uneventfully from surgery and had no evidence of recurrence on long-term follow-up. We propose that EEO, which occurs in the absence of immune suppression or diabetes, is a clinical entity that is distinct from the more commonly diagnosed malignant external otitis and that the management of EEO is primarily surgical debridement with skin grafting.
- 1 April 2010
- Published by Wolters Kluwer Health in Otology & Neurotology
- Vol. 31 (3) , 455-459
Clinical Utility of Electrocochleography in the Diagnosis and Management of Ménière's Disease
Objective: Evaluate the clinical use of electrocochleography (ECoG) for diagnosis/treatment of Ménière's disease among members of the American Otological Society (AOS) and American Neurotology Society (ANS). Subjects: Clinically active members of the AOS/ANS. Main Outcome Measure: Survey responses. Results: A total of 143 responses were received from 344 possible respondents (41.6%). In suspected cases of Ménière's disease, 45.5% of respondents did not use ECoG at all, 17.5 % used ECoG routinely, and 37.1% used it only in questionable cases. Electrocochleography users differed widely in electrode approach and stimulus modality used, with extratympanic approach and click stimuli used most frequently. Most respondents (73.2%) thought that ECoG is a test of indeterminate value. Only 3.6% required an abnormal ECoG to diagnose endolymphatic hydrops. An abnormal test was a requirement to proceed with ablative therapy for just 8.6% of respondents. Still, 77.9% think that ECoG findings do fluctuate with activity of the disorder, but only 18.0% agree that when the ECoG reverts to normal, one can predict remission of symptoms. Almost half of respondents (46.7%) reported that they have now stopped ordering ECoG due to variability in results and lack of correlation with their patients' symptoms. Conclusion: Among AOS/ANS members, there is low clinical use of ECoG in diagnosis/management of Ménière's disease. For approximately half of respondents, ECoG has no role in their clinical practice. Electrocochleography was used routinely by only 1 in 6 respondents. Those who used ECoG differed widely in electrode placement and type of stimuli paradigm used.
- 1 April 2010
- Published by Wolters Kluwer Health in Otology & Neurotology
- Vol. 31 (3) , 455-459
Clinical Utility of Electrocochleography in the Diagnosis and Management of Ménière's Disease
Objective: Evaluate the clinical use of electrocochleography (ECoG) for diagnosis/treatment of Ménière's disease among members of the American Otological Society (AOS) and American Neurotology Society (ANS). Subjects: Clinically active members of the AOS/ANS. Main Outcome Measure: Survey responses. Results: A total of 143 responses were received from 344 possible respondents (41.6%). In suspected cases of Ménière's disease, 45.5% of respondents did not use ECoG at all, 17.5 % used ECoG routinely, and 37.1% used it only in questionable cases. Electrocochleography users differed widely in electrode approach and stimulus modality used, with extratympanic approach and click stimuli used most frequently. Most respondents (73.2%) thought that ECoG is a test of indeterminate value. Only 3.6% required an abnormal ECoG to diagnose endolymphatic hydrops. An abnormal test was a requirement to proceed with ablative therapy for just 8.6% of respondents. Still, 77.9% think that ECoG findings do fluctuate with activity of the disorder, but only 18.0% agree that when the ECoG reverts to normal, one can predict remission of symptoms. Almost half of respondents (46.7%) reported that they have now stopped ordering ECoG due to variability in results and lack of correlation with their patients' symptoms. Conclusion: Among AOS/ANS members, there is low clinical use of ECoG in diagnosis/management of Ménière's disease. For approximately half of respondents, ECoG has no role in their clinical practice. Electrocochleography was used routinely by only 1 in 6 respondents. Those who used ECoG differed widely in electrode placement and type of stimuli paradigm used.